Durable Improvement in Generic and Fibroid-Specific Quality of Life in Women Treated with Transcervical Fibroid Ablation with the Sonata System After Three Years.

MedStar author(s):
Citation: Journal of Gynecologic Surgery. 38(2):143-147, 2022 Apr 01.PMID: 35497488Institution: MedStar Washington Hospital CenterDepartment: Obstetrics and GynecologyForm of publication: Journal ArticleMedline article type(s): Journal ArticleYear: 2022ISSN:
  • 1042-4067
Name of journal: Journal of gynecologic surgeryAbstract: Conclusions: Women treated by TFA with the Sonata System for symptomatic uterine fibroids reported durable improvements in generic and fibroid-specific QOL, as well as clinically meaningful increases in QALYs over 3 years. Clinical Trials.gov ID: NCT02228174. (J GYNECOL SURG 38:143). Copyright © Kelly Roy et al. 2022; Published by Mary Ann Liebert, Inc.Methods: The SONATA trial was a prospective multicenter interventional trial that assessed the safety and efficacy of TFA for treatment of women with symptomatic uterine fibroids. Change in generic health status was assessed with the EuroQol 5-Dimension questionnaire (0-1 scale). Fibroid-specific quality of life (QOL) was measured on a 0 to 100 scale with the health-related quality of life subscale of the Uterine Fibroid Symptom and Quality-of-Life (UFS-QOL). The number of QALYs gained relative to baseline and cumulative QALYs were calculated using the area under the curve at each follow-up visit over 3 years.Objective: To determine quality-adjusted life years (QALYs) over 3 years after transcervical fibroid ablation (TFA) with the Sonata System.Results: Among 147 women receiving TFA, fibroid-specific QOL increased from 40 +/- 21 at baseline to 84 +/- 19 at 1 year and 83 +/- 23 at 3 years (p < 0.001). Generic QOL increased from 0.72 +/- 0.21 at baseline to 0.89 +/- 0.12 at 1 year and 0.88 +/- 0.16 at 3 years (p < 0.001). Over 3 years, TFA resulted in 1.24 +/- 0.64 QALYs gained when using fibroid-specific health utility scores and 0.49 +/- 0.61 QALYs gained when using generic health utility scores. Cumulative QALYs experienced at 3 years as a percentage of perfect health were 82% with fibroid-specific scores and 88% with generic health scores.All authors: Robinson JK, Roy KFiscal year: FY2022Digital Object Identifier: Date added to catalog: 2022-07-06
Holdings
Item type Current library Collection Call number Status Date due Barcode
Journal Article MedStar Authors Catalog Article 35497488 Available 35497488

Conclusions: Women treated by TFA with the Sonata System for symptomatic uterine fibroids reported durable improvements in generic and fibroid-specific QOL, as well as clinically meaningful increases in QALYs over 3 years. Clinical Trials.gov ID: NCT02228174. (J GYNECOL SURG 38:143). Copyright © Kelly Roy et al. 2022; Published by Mary Ann Liebert, Inc.

Methods: The SONATA trial was a prospective multicenter interventional trial that assessed the safety and efficacy of TFA for treatment of women with symptomatic uterine fibroids. Change in generic health status was assessed with the EuroQol 5-Dimension questionnaire (0-1 scale). Fibroid-specific quality of life (QOL) was measured on a 0 to 100 scale with the health-related quality of life subscale of the Uterine Fibroid Symptom and Quality-of-Life (UFS-QOL). The number of QALYs gained relative to baseline and cumulative QALYs were calculated using the area under the curve at each follow-up visit over 3 years.

Objective: To determine quality-adjusted life years (QALYs) over 3 years after transcervical fibroid ablation (TFA) with the Sonata System.

Results: Among 147 women receiving TFA, fibroid-specific QOL increased from 40 +/- 21 at baseline to 84 +/- 19 at 1 year and 83 +/- 23 at 3 years (p < 0.001). Generic QOL increased from 0.72 +/- 0.21 at baseline to 0.89 +/- 0.12 at 1 year and 0.88 +/- 0.16 at 3 years (p < 0.001). Over 3 years, TFA resulted in 1.24 +/- 0.64 QALYs gained when using fibroid-specific health utility scores and 0.49 +/- 0.61 QALYs gained when using generic health utility scores. Cumulative QALYs experienced at 3 years as a percentage of perfect health were 82% with fibroid-specific scores and 88% with generic health scores.

English

Powered by Koha